8-K
SAB Biotherapeutics, Inc. (SABS)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Dateof Report (Date of earliest event reported): December 31, 2021
SABBiotherapeutics, Inc.
(Exactname of registrant as specified in its charter)
| Delaware | 001-39871 | 85-3899721 |
|---|---|---|
| (State or other jurisdiction<br><br> <br>of incorporation) | (Commission<br><br> <br>File Number) | (I.R.S. Employer<br><br> <br>Identification No.) |
2100East 54th Street North
SiouxFalls, SD 57104
(Addressof Principal Executive Offices) (Zip Code)
(605)679-6980
(Registrant’sTelephone Number, Including Area Code)
NotApplicable
(FormerName or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
|---|---|---|
| Common<br> Stock, $0.0001 par value per share | SABS | Nasdaq<br> Stock Market LLC |
| Warrants,<br> each exercisable for one share of Common Stock at an exercise price of $11.50 per share | SABSW | Nasdaq<br> Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item5.02 Departure of Directors or Certain Officers;Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 31, 2021, Charles H. Randall, Chief Strategy Officer of SAB Biotherapeutics, Inc. (the “Company”), resigned. The Company and Mr. Randall are finalizing the terms of a release and severance under his employment agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 6, 2022
| SAB<br> Biotherapeutics, Inc. | |
|---|---|
| By: | /s/ Russell Beyer |
| Russell<br> Beyer | |
| Chief<br> Financial Officer |